Ignite a New Approach
to Cancer Care

The advent of cancer immunotherapies, in particular first-generation PD-1 inhibitors, has represented a major step forward for treating certain cancers. However, most patients with cancer never benefit from today’s immunotherapies because many tumors are immune excluded: shut off from beneficial immune attack by barriers that actively keep the immune system’s soldiers, CD8+ T cells, out. At ImmunoGenesis, we are engineering next-generation immunotherapies designed for these hardest-to-treat tumors. Our therapies are designed to dismantle the very mechanisms of resistance that make these tumors invisible to current treatments. These therapies have the potential to become a new foundation of immunotherapy.

A team with vision + the skills to deliver

We understand immune resistance pathways. Our team is using rational drug design to target these resistance mechanisms and build therapies that unleash the immune system against tumors.

Meet the team

We understand immune resistance pathways. Our team is using rational drug design to target these resistance mechanisms and build therapies that unleash the immune system against tumors.

Rewriting the rules

Closing the gap in immunotherapy

Immunotherapy has transformed cancer treatment. But not for most patients. Only 15% of people with cancer benefit from first-generation PD-1 inhibitors because the majority of tumors are immune excluded. These tumors block immune recognition or stop T cells at the margins, often rendering first-generation PD-1 inhibitors ineffective and leaving patients with few effective options. Tumors with significant immune exclusion represent 4 of the most common causes of cancer death in the United States.

Why do these tumors resist? First-generation PD-1 inhibitors have a single mechanism: to block the PD-1 inhibitory signal when T cells are at the tumor and poised to attack. If T cells are locked out and unable to access the tumor, blockade of the inhibitory signal is not enough. We now know that, in addition to signal blockade, an effective drug must also breach the inhibitory wall, allowing T cells to traffic to the tumor.

ImmunoGenesis was founded to close this gap. Our lead molecule, IMGS-001, is a multifunctional cytotoxic immune checkpoint inhibitor (ICI) designed to

  • Destroy the barriers keeping T cells out
  • Provide best-in-class blockade against the PD-1 inhibitory signal
  • Activate T cells once they are at the tumor and ready to attack

We aim to redefine what’s treatable.

Re-envisioning treatment for immune-excluded tumors

First-generation PD-1 inhibitors have not demonstrated significant effectiveness in immune-excluded tumors. The industry has tried to address this shortfall with combinations using first-generation PD-1 inhibitors as their base. Although thousands of combination trials have been tried, very few have demonstrated success. Adding layers onto an ineffective base has not solved immune exclusion.

Starting at the root: the biology of immune exclusion

The PD-1 pathway is one of the body’s main immune checkpoints, or “brakes,” used by healthy cells to prevent autoimmunity. Tumors exploit this brake to shut down T cells. PD-1 establishes the brake by binding to 2 ligands, PD-L1 and PD-L2. First-generation PD-1 inhibitors block this immune checkpoint, which allows T cells already at the tumor to fight the cancer. But in the majority of cancers, T cells are locked out because they are immune excluded, rendering this single-mechanism approach ineffective.

We believe our lead molecule addresses this gap. It is designed to marry best-in-class blockade of the PD-1 inhibitory signal with robust effector function that eliminates the barriers keeping T cells away from the tumor. This multifunctionality allows our drug to potentially work where current therapies may lack efficacy.

See what we’ve designed

Our lead

IMGS-001

Our lead, IMGS-001, is a cytotoxic ICI: the first antibody designed to block both PD-L1 and PD-L2 and eliminate the suppressive cells that protect tumors from immune attack. By dismantling these defenses, IMGS-001 targets the root pathology of immune-excluded tumors.

IMGS-001 could establish a stronger foundation of targeting the PD-1 pathway by addressing T-cell exclusion and the PD-1 inhibitory signal in a single molecule. This molecule has the potential to drive robust efficacy as a monotherapy that can become foundational for future combinations. This efficacy is critical, because the first generation of PD-1 inhibitors do not have monotherapy efficacy in immune-excluded tumors, which many believe is why combinations have largely failed.

The differentiated efficacy of IMGS-001’s unique mechanism has been demonstrated across preclinical models, showing curative impact where the current drugs do not. This multifunctional mechanism is designed to do what first-generation PD-1 inhibitors could not: unleash T cells to infiltrate, activate, and destroy tumors once thought untreatable.

Reverse hypoxia in the tumor microenvironment

IMGS-101

Tumor hypoxia, characterized by low oxygen within the tumor microenvironment (TME), is one of the most powerful barriers to immunotherapy. In solid tumors like pancreatic, prostate, and head and neck cancers, the majority of the tumor is hypoxic. This prevents T cells from entering, creating large zones of immune resistance where ICIs can be rendered ineffective because the very cells they are attempting to activate, T cells, are absent.

IMGS-101 (evofosfamide) was designed to dismantle this barrier. It is a DNA-alkylating prodrug that remains inactive in normal tissue but is activated in hypoxic tumor regions. Once activated, it remodels the TME by reversing tumor hypoxia, allowing T cells to traffic back into the tumor and restoring sensitivity to immune checkpoint blockade.

This approach reflects ImmunoGenesis founder Dr. Michael Curran’s commitment to rational drug design: targeting the fundamental weaknesses that make tumors resistant. Evofosfamide has already been studied in more than 1,600 patients with early clinical data showing encouraging activity. In 2025, IMGS-101 advanced into a phase 1/2 clinical trial, aiming to make solid tumors more accessible to immune destruction.

Potent STING agonist

IMGS-203

IMGS-203 is a novel intratumoral stimulator of interferon genes (STING) agonist designed to overcome the profound immune suppression characteristic of glioblastoma multiforme (GBM), the most common and lethal brain tumor. By reprogramming the immune-suppressive myeloid stroma into a proinflammatory state, IMGS-203 restores anti-tumor immunity within the TME. Direct intratumoral administration of IMGS-203 ensures high local exposure, precise tumor targeting, and potent immune activation while minimizing off-target effects.

We’re just getting started

We’re just getting started

We are committed to creating a new foundation of treatments for immune-excluded tumors, building a complementary pipeline from the very beginning. We have clinical trials underway and the next several years mapped out.

Explore our plans

Investors

Re-envision

Cancer Care

Building the foundation for the future of immunotherapy.

Learn more

A $70B+ market opportunity

Of the 1.8 million new cancer cases each year in the United States, more than half are immune-excluded tumors, the very cancers that resist first-generation PD-1 inhibitors. These patients represent the largest unmet need in immuno-oncology and a treatment category worth over $70 billion.

Clinical trials underway

IMGS-001 and IMGS-101 are advancing in the clinic, supported by strong preclinical data, early FDA interactions, and a secure manufacturability profile. With a defensible IP position and the potential for 2 differentiated mechanisms, ImmunoGenesis is positioned for durable leadership in the next wave of immunotherapy.

Expanding reach

By addressing immune-excluded tumors, we aim to dramatically expand the population that benefits from immune checkpoint therapy. Our goal is clear: redefine what’s treatable, deliver broader patient impact, and capture the next era of immuno-oncology growth.

Investors

Re-envision

Cancer Care

Building the foundation for the future of immunotherapy.

Learn more

A $70B+ market opportunity

Of the 1.8 million new cancer cases each year in the United States, more than half are immune-excluded tumors, the very cancers that resist first-generation PD-1 inhibitors. These patients represent the largest unmet need in immuno-oncology and a treatment category worth over $70 billion.

Clinical trials underway

IMGS-001 and IMGS-101 are advancing in the clinic, supported by strong preclinical data, early FDA interactions, and a secure manufacturability profile. With a defensible IP position and the potential for 2 differentiated mechanisms, ImmunoGenesis is positioned for durable leadership in the next wave of immunotherapy.

Expanding reach

By addressing immune-excluded tumors, we aim to dramatically expand the population that benefits from immune checkpoint therapy. Our goal is clear: redefine what’s treatable, deliver broader patient impact, and capture the next era of immuno-oncology growth.